The DRC8 Knockout Raji Polyclonal Cells comprise a ready-to-use CRISPR/Cas9-edited polyclonal population of Raji B lymphocytes featuring targeted disruption of the DRC8 gene. This heterogeneous pool harbors a diverse array of loss-of-function mutations, avoiding the biases of monoclonal selection. The product provides a robust platform for investigating the uncharacterized DRC8 gene in a human B cell context, facilitating functional genomics and phenotypic screening.
Raji cells are an Epstein-Barr virus (EBV)-positive B lymphocyte line derived from a Burkitt lymphoma patient. They are widely employed in immunological and cancer research for their capacity to model B cell functions such as antibody production, antigen presentation, and humoral immunity. As a suspension cell line with high transfection efficiency, Raji cells offer a versatile and well-characterized host for CRISPR-mediated gene disruption studies, especially those probing B cell signaling, lymphoma pathogenesis, and virus?Chost interactions.
The DRC8 gene remains largely unannotated, with no characterized biological pathways, upstream regulators, downstream targets, or interacting partners reported to date. It is hypothesized to participate in cellular regulation and signaling, though its mechanistic role is undefined. This knockout model enables de novo functional discovery, allowing researchers to map its involvement in signaling networks by assessing global changes in gene expression, protein phosphorylation, or protein?Cprotein interactions. The polyclonal nature reveals a spectrum of knockout-induced phenotypes on growth, survival, or differentiation, potentially uncovering functions masked in clonal populations.
In Raji B cells, DRC8 disruption directly interrogates gene function in lymphocyte-specific processes such as proliferation, apoptosis, and immune signaling. The EBV-positive background allows assessment of DRC8??s influence on viral latency or transformation. Additionally, the polyclonal population can be employed in pooled CRISPR screens to evaluate gene essentiality or identify synthetic lethal partners, offering a comprehensive view of its functional landscape.
Typical applications include Western blotting and RT-qPCR for knockout confirmation, flow cytometry for surface marker phenotyping, and functional assays for proliferation and apoptosis. RNA-seq profiling can uncover DRC8-dependent transcriptional networks. These capabilities suit the product for CRISPR screening, functional validation, and exploratory B cell research. For further information, contact Ascent Research.
